Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The GluA2-containing AMPA receptor is a subtype of ionotropic glutamate receptor that mediates the majority of fast excitatory synaptic transmission in the central nervous system [Traynelis et al., 2010, Pharm Rev]. The inclusion of the GluA2 subunit, particularly in its Q/R edited form, is a primary determinant of the receptor's biophysical properties, rendering the channel impermeable to calcium ions and protecting neurons from excitotoxicity [Isaac et al., 2007, Neuron]. Transmembrane AMPA receptor regulatory proteins (TARPs), specifically TARP γ-2 (also known as Stargazin), act as essential auxiliary subunits that regulate the trafficking of these receptors to the postsynaptic membrane and modulate their gating kinetics [Jackson & Nicoll, 2011, Neuron]. Dysregulation of GluA2-containing receptors is implicated in various neurological disorders, including epilepsy, amyotrophic lateral sclerosis (ALS), and neurodegenerative diseases like Alzheimer's [Kwak & Weiss, 2006, Neurobiol Dis; Guntupalli et al., 2016, Mol Brain]. Pharmacological targeting of these receptors often involves non-competitive antagonists or allosteric modulators, with some newer compounds specifically targeting the interaction between the receptor and its TARP subunits to achieve regional or functional selectivity [Kato et al., 2016, Nature Medicine]. Understanding the stoichiometry and auxiliary protein associations of these receptors is crucial for developing therapies that balance efficacy with minimized side effects such as sedation or motor impairment [French et al., 2012, Neurology].
Non-competitive antagonism of the AMPA receptor [French et al., 2012, Neurology]; TARP-dependent negative allosteric modulation [Kato et al., 2016, Nature Medicine]; Positive allosteric modulation [Lynch, 2006, Ampakines].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate ionotropic receptor AMPA type subunit 2-containing receptor complex (GluA2-containing AMPAR).